{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T17:42:18Z","timestamp":1776361338340,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pharma.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:04:59Z","timestamp":1764867899000},"page":"505-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyse de risques selon la m\u00e9thode AMDEC appliqu\u00e9e au circuit pharmaceutique d\u2019un m\u00e9dicament de th\u00e9rapie g\u00e9nique ex vivo Casgevy\u00ae dans la b\u00eata-thalass\u00e9mie"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8044-7710","authenticated-orcid":false,"given":"Agathe","family":"Vermersch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Gervaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Rascle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Laflotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Tawil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Delpech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9rane","family":"Schwiertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Br\u00e9ant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharma.2025.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.pharma.2025.12.003_bib0115","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharma.2025.12.003_bib0120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.pharma.2025.12.003_bib0125","doi-asserted-by":"crossref","first-page":"727905","DOI":"10.1155\/2013\/727905","article-title":"The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders","volume":"2013","author":"Angastiniotis","year":"2013","journal-title":"Sci World J"},{"issue":"7","key":"10.1016\/j.pharma.2025.12.003_bib0130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3109\/07853890.2015.1091942","article-title":"Increasing prevalence of thalassemia in America: implications for primary care","volume":"47","author":"Sayani","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.pharma.2025.12.003_bib0135","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in \u03b2-thalassemia","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.pharma.2025.12.003_bib0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.pharma.2025.12.003_bib0145","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2025.12.003_bib0150","series-title":"Recommandations SFPO sur le circuit hospitalier des m\u00e9dicaments de th\u00e9rapies innovantes (MTI)\u00a0\u2013\u00a0V2","year":"2023"},{"key":"10.1016\/j.pharma.2025.12.003_bib0155","series-title":"The systems approach to quality Assurance for Pharmacy Practice: a framework for mitigating risk","author":"Cooney","year":"2012"},{"key":"10.1016\/j.pharma.2025.12.003_bib0160","series-title":"Fiche 34\u00a0: Proposer des pistes dans trois directions\u00a0: 1. mettre en \u0153uvre des m\u00e9thodes d\u2019analyse de risques de nature quantitative, 2. introduire la formation par simulation, 3. donner une place aux patients dans la gestion des risques [Internet]","year":"2012"},{"issue":"4","key":"10.1016\/j.pharma.2025.12.003_bib0165","first-page":"315","article-title":"Approche comment\u00e9e par \u00e9tape pour r\u00e9aliser une AMDEC dans le cadre du circuit du m\u00e9dicament","volume":"53","author":"Boul\u00e9","year":"2018","journal-title":"Pharm Hosp Clin"},{"issue":"1","key":"10.1016\/j.pharma.2025.12.003_bib0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/10781552211053253","article-title":"Application of the failure mode and effects analysis (FMEA) to identify vulnerabilities and opportunities for improvement prior to implementing a computerized prescription order entry (CPOE) system in a university hospital oncology clinic","volume":"29","author":"Joly-Mischlich","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.pharma.2025.12.003_bib0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2753.2011.01799.x","article-title":"The AM\u00c9LIE project: failure mode, effects and criticality analysis: a model to evaluate the nurse medication administration process on the floor","volume":"19","author":"Nguyen","year":"2013","journal-title":"Eval Clin Pract"},{"issue":"1","key":"10.1016\/j.pharma.2025.12.003_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-021-11369-5","article-title":"Application of failure mode and effects analysis (FMEA) to improve medication safety in the dispensing process\u00a0\u2013\u00a0a study at a teaching hospital, Sri Lanka","volume":"21","author":"Anjalee","year":"2021","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.pharma.2025.12.003_bib0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/qshc.2003.007914","article-title":"Use of a systematic risk analysis method to improve safety in the production of paediatric parenteral nutrition solutions","volume":"14","author":"Bonnabry","year":"2005","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.pharma.2025.12.003_bib0190","series-title":"M\u00e9dicaments de th\u00e9rapie innovante de type CAR-T cells anti-cd19 autoris\u00e9s sur le march\u00e9 europ\u00e9en\u00a0: description et gestion des risques du circuit du m\u00e9dicament","author":"Zappitelli","year":"2019"},{"key":"10.1016\/j.pharma.2025.12.003_bib0195","series-title":"Mise en place d\u2019une nouvelle activit\u00e9 de MTI \u00e0 base de lymphocytes T g\u00e9n\u00e9tiquement modifi\u00e9s (CAR-T cells) \u00e0 la PUI de l\u2019I.CHU.SE","author":"Castellino","year":"2022"},{"issue":"6","key":"10.1016\/j.pharma.2025.12.003_bib0200","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.pharma.2023.04.001","article-title":"Circuit pharmaceutique du m\u00e9dicament de th\u00e9rapie innovante (MTI) en France\u00a0: \u00e9tat des lieux et perspectives","volume":"81","author":"Fabri","year":"2023","journal-title":"Ann Pharm Fr"},{"issue":"6","key":"10.1016\/j.pharma.2025.12.003_bib0205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/intqhc\/mzp043","article-title":"Integration of prospective and retrospective methods for risk analysis in hospitals","volume":"21","author":"Kessels-Habraken","year":"2009","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.pharma.2025.12.003_bib0105","series-title":"14es Journ\u00e9es Nationales Actualit\u00e9s en Oncologie, Congr\u00e8s de la SFPO","article-title":"Innovation pharmaceutique\u00a0: oui mais \u00e0 quel prix\u00a0? [r\u00e9sum\u00e9]","author":"Cohet","year":"2023"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925001919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450925001919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:45:53Z","timestamp":1776357953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450925001919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0003450925001919"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2025.12.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyse de risques selon la m\u00e9thode AMDEC appliqu\u00e9e au circuit pharmaceutique d\u2019un m\u00e9dicament de th\u00e9rapie g\u00e9nique ex vivo Casgevy\u00ae dans la b\u00eata-thalass\u00e9mie","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}